High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients.
Leonardo LorenteMaría M MartínLuis RamosMónica ArguesoJuan J CáceresJordi Solé-ViolánAlejandro JiménezJuan M Borreguero-LeónAgustín F González-RiveroJosune OrbeJosé A RodríguezJosé A PáramoPublished in: BMC neurology (2019)
The new findings of our study were that non-surviving MMCAI patients showed higher serum TIMP-1 levels during the first week of MMCAI that surviving patients, and those levels during the first week of MMCAI could be used as mortality biomarkers.